The Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2030, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early. We do not assume renewals in our determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company’s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.

Supplemental cash flow information related to operating leases is as follows (dollars in thousands):

	Three Months Ended
	March 31, 2019
Cash payments for operating leases	$	734
Right-of-use assets obtained in exchange for operating lease obligations		13,560

	March 31, 2019
Weighted-average remaining lease term	9.9 years
Weighted-average discount rate		9.0	%

Future minimum non-cancelable payments under operating leases as of March 31, 2019, were as follows (in thousands):

	Operating Leases
Remainder of 2019	$	2,796
2020		3,047
2021		3,086
2022		2,714
2023		2,610
Thereafter		18,690
Total future lease payments	$	32,943
Less imputed interest		12,072
Present value of lease liabilities	$	20,871

During the three months ended March 31, 2019 and 2018, the Company recorded operating lease cost of $0.5 million and $0.3 million, respectively. As of March 31, 2019, the Company had no leases that have not yet commenced.

The Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company.